Stock Events

Valerio Therapeutics 

€0.1
2
+€0+0% Friday 19:50

Statistics

Day High
0.1
Day Low
0.09
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
16.31M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

29AprExpected
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-0.18
-0.12
-0.06
0
Expected EPS
0
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow C4X.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer; Revocan phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP inhibitor resistance in second-line maintenance treatment of recurrent ovarian cancer; and phase 1b/2 trial evaluating AsiDNA in combination with radiotherapy in recurrent highgrade glioma in children. It also develops VIO-01, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, a chemistry platform for building new molecules, which includes OX400, a decoy DNA platform. It has collaboration agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of recurrent ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was founded in 1997 and is headquartered in Paris, France.
Show more...
CEO
Dr. Shefali Agarwal M.D., MPH
Employees
19
Country
FR
ISIN
FR0010095596
WKN
000A0HMXA

Listings